Granulocyte-macrophage colony-stimulating factor (GM-CSF), Colony-stimulating factor (CSF), Molgramostin, Sargramostim, rHuman GM-CSF (Granulocyte-macrophage colony-stimulating factor )
- Known as:
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), Colony-stimulating factor (CSF), Molgramostin, Sargramostim, rHuman GM-CSF (Granulocyte-macrophage colony-stimulating factor )
- Catalog number:
- RF0036-
- Product Quantity:
- 10ug
- Category:
- -
- Supplier:
- Agren
- Gene target:
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) Colony-stimulating (CSF) Molgramostin Sargramostim rHuman GM-CSF (Granulocyte-macrophage )
Related genes to: Granulocyte-macrophage colony-stimulating factor (GM-CSF), Colony-stimulating factor (CSF), Molgramostin, Sargramostim, rHuman GM-CSF (Granulocyte-macrophage colony-stimulating factor )
- Gene:
- AACS NIH gene
- Name:
- acetoacetyl-CoA synthetase
- Previous symbol:
- -
- Synonyms:
- FLJ12389, SUR-5, ACSF1
- Chromosome:
- 12q24.31
- Locus Type:
- gene with protein product
- Date approved:
- 2003-06-02
- Date modifiied:
- 2015-08-24
- Gene:
- AASDH NIH gene
- Name:
- aminoadipate-semialdehyde dehydrogenase
- Previous symbol:
- -
- Synonyms:
- NRPS998, LYS2, ACSF4
- Chromosome:
- 4q12
- Locus Type:
- gene with protein product
- Date approved:
- 2007-10-17
- Date modifiied:
- 2015-08-26
- Gene:
- CLEC2B NIH gene
- Name:
- C-type lectin domain family 2 member B
- Previous symbol:
- CLECSF2
- Synonyms:
- AICL, HP10085
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-07
- Date modifiied:
- 2016-10-05
- Gene:
- CLEC3A NIH gene
- Name:
- C-type lectin domain family 3 member A
- Previous symbol:
- CLECSF1
- Synonyms:
- -
- Chromosome:
- 16q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-10-12
- Date modifiied:
- 2016-10-05
- Gene:
- CLEC4A NIH gene
- Name:
- C-type lectin domain family 4 member A
- Previous symbol:
- CLECSF6
- Synonyms:
- DCIR, DDB27, CD367
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 2001-02-01
- Date modifiied:
- 2016-10-05
Related products to: Granulocyte-macrophage colony-stimulating factor (GM-CSF), Colony-stimulating factor (CSF), Molgramostin, Sargramostim, rHuman GM-CSF (Granulocyte-macrophage colony-stimulating factor )
Related articles to: Granulocyte-macrophage colony-stimulating factor (GM-CSF), Colony-stimulating factor (CSF), Molgramostin, Sargramostim, rHuman GM-CSF (Granulocyte-macrophage colony-stimulating factor )
- Colony-stimulating factor 2 (CSF2) is an embryokine used between days 5 and 7 of culture to improve embryonic development. We evaluated its use from Day 4 and throughout the culture period in a reduced nutrient concentrations culture medium. Presumptive zygotes were assigned to three treatments: Control - synthetic oviduct fluid (SOF), CSF2 D1 (SOF + CSF2 from Day 1-7), CSF2 D4 (SOF + CSF2 from Day 4-7). Cleavage rates on Day 4 and blastocyst rates on days 6 and 7 were evaluated. On Day 7, expanded blastocysts were used to assess mitochondrial activity, lipid quantification, total cell number, gene expression and DNA methylation patterns. Embryo development data were analyzed using the chi-square test (P ≤ 0.05). Data normally distributed were analyzed with ANOVA and Tukey's test, while non-normally distributed data were evaluated using the Kruskal-Wallis and Mann-Whitney tests. Cleavage and blastocyst rates on Day 7 were similar (P > 0.05) among treatments. Of 11 genes evaluated, only Placenta-specific 8 presented a lower number of transcripts (P ≤ 0.05) in embryos cultured with CSF2 from Day 4. Assessments of DNA methylation, lipid droplet staining, mitochondrial activity and total cell number showed no significant differences among treatments (P > 0.05). In conclusion, CSF2 had no effect on the assessed parameters when a culture medium with reduced nutrient concentrations was used, and can be used throughout the entire culture period without affecting embryo production and developmental kinetics compared to CSF2 added on Day 4. - Source: PubMed
Publication date: 2025/04/29
Nicolás Ana Caroline Chaves Vallde Oliveira Leme LigianeMoura Amanda OliveiraKussano Nayara Ribeirode Siqueira EmivaldoFranco Maurício MachaimDode Margot Alves Nunes - Blockade of immune checkpoints, such as programmed death-ligand 1 (PD-L1), has shown promise in cancer treatment; however, clinical response remains limited in many cancer types. Our previous research demonstrated that p300/CBP mediates the acetylation of the PD-L1 promoter, regulating PD-L1 expression. In this study, we further investigated the role of the p300/CBP bromodomain in regulating PD-L1 expression using CCS1477, a selective bromodomain inhibitor developed by our team. We found that the p300/CBP bromodomain is essential for H3K27 acetylation at PD-L1 enhancers. Inhibiting this modification significantly reduced enhancer activity and PD-L1 transcription, including exosomal PD-L1, which has been implicated as key contributors to resistance against PD-L1 blockade therapy in various cancers. Furthermore, CCS1477 treatment resulted in a marked reduction of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) by inhibiting key cytokines such as IL6, CSF1, and CSF2, which are crucial for MDSC differentiation and recruitment. By reducing PD-L1 expression and modulating the immunosuppressive TME, CCS1477 creates a more favorable environment for tumor-infiltrating lymphocytes, significantly enhancing the efficacy of immune checkpoint blockade (ICB) therapy. Notably, these effects were observed in both prostate cancer and melanoma models, underscoring the broad therapeutic potential of p300/CBP bromodomain inhibition in improving ICB outcomes. - Source: PubMed
Publication date: 2025/04/21
Liu JinghuiWang XinyiHe DahengMaasoumyhaghighi HamedNouri MansourehWu MengPeng JiaRao XiongjianWang RuixinWu SaiWang JianlinBrooks NigelPegg NeilFrese KrisLi ZhiguoLiu Xiaoqi - Granulocyte-macrophage colony-stimulating factor (GM-CSF: CSF2) plays a crucial role in the pathogenesis of autoimmune diseases. The basic helix-loop-helix family member e40 (BHLHE40) gene is important for GM-CSF production in CD4 T cells. However, the relationship between the expression of these genes and rheumatoid arthritis (RA) remains unclear, particularly in interleukin-1 (IL-1)-enriched inflammatory sites. Therefore, we investigated the expression of BHLHE40 and CSF2 in CD4 T cells in RA. - Source: PubMed
Ishigaki ShoSuzuki KatsuyaTakeshita MasaruKaneko Yuko - Seminal fluid introduced into the female reproductive tract following unprotected coitus initiates an inflammation-like response in the cervical tissues that stimulates immune tolerance to male seminal fluid alloantigens and promotes immune adaptation for pregnancy. This response commences when seminal fluid factors induce genes encoding pro-inflammatory cytokines and chemokines including CSF2, IL6, and CXCL8, that in turn cause recruitment of macrophages, dendritic cells, and T cells into the epithelial and stromal layers. Various signaling agents present in seminal plasma provoke the post-coital pro-inflammatory activation and regulate the quality of immune response. However, the factors identified to date do not account for all the biological activity within seminal fluid, implying sperm-associated factors may also contribute. In this chapter, we report methods for evaluating the effects of human seminal fluid components (seminal plasma and sperm) on the female reproductive tract immune response in primary and immortalized ectocervical epithelial cells in vitro. - Source: PubMed
Sharkey David JLyons Hannah EChan Hon YeungRobertson Sarah A - Increasing evidence suggests that resistance to 5-fluorouracil (5FU) and oxaliplatin (OXP) in colorectal cancer (CRC) is linked to poor prognosis. This study aimed to probe the effect of colony-stimulating factor 2 (CSF2) on the resistance of CRC to 5FU and OXP. - Source: PubMed
Publication date: 2025/04/09
Zhou HairongGao ZhenyuanWu XiaoWang YapingZhang Lu